Program
NI-0101
Also written as “Cohort B: paridiprubart” and “SOC plus 15mg/kg EB05 IV”.
Its studies are mostly in Respiratory Distress Syndrome · COVID-19 · Arthritis, Rheumatoid, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PPD Development, LP | 22 open or running | phase 2since Nov 20, 2024 | Nov 20, 2024 | Jul 2028phase 2 · NCT06703073 |
| Edesa Biotech | 10 open or running | phase 3since May 21, 2020 | May 21, 2020 | none ahead |
| Light Chain Bioscience - Novimmune | 10 open or running | phase 2since Jun 26, 2017 | Jun 26, 2017 | none ahead |
Also a collaborator on its studies: jss-medical-research-inc, inflarx-gmbh and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2017First study: phase 2 study in Arthritis, RheumatoidNew to Light Chain Bioscience - NovimmuneLight Chain Bioscience - Novimmune · NCT03241108 · 90 enrolled · Bosnia and Herzegovina, Bulgaria, Georgia and more
- May 21, 2020Edesa Biotech's first study: phase 3 study in COVID-19New to Edesa BiotechEdesa Biotech · NCT04401475 · 278 enrolled · United States, Canada
- Nov 20, 2024PPD Development, LP's first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to PPD Development, LPPPD Development, LP · NCT06703073, NCT06701669
Ahead
- Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06703073
- Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06701669
TargetBeta
“A monoclonal antibody directed against toll-like receptor 4 (TLR4), ”NCIt, by rule
Other programs on TLR4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| INI-2004rule | inimmune-corporation | phase 2 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06703073Respiratory Distress Syndrome · United States | 2 | Recruiting | PPD Development, LP | Jul 2028 | 600 |
| NCT06701669Respiratory Distress Syndrome · United States | 2 | Recruiting | PPD Development, LP | Jul 2028 | 200 |
| NCT04401475COVID-19 · United States, Canada | 3 | Terminated | Edesa Biotech | Jul 22, 2024 | 278 |
| NCT03241108Arthritis, Rheumatoid · Bosnia and Herzegovina, Bulgaria, Georgia and more | 2 | Completed | Light Chain Bioscience - Novimmune | Jun 20, 2018 | 90 |
How it is read
Names in the registry
- “Cohort B: paridiprubart”, 2 entries
- “SOC plus 15mg/kg EB05 IV”, 1 entry
- “NI-0101”, 1 entry
Codes read as this program: EB05.
Conditions, from the studies’ own filings
- Respiratory Distress Syndrome, 2 studies
- COVID-19, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.